Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From the REISAMIC Registry

Thomas Hueso; Justin Cagnat; Kaïssa Ouali; M. Haberstich; Benoît Henry; Alina Danu; Camille Bigenwald; Mansouria Merad; Sabine Messayke; Ariane Laparra; Madona Sakkal; Cristina Smolenschi; Antoine Hollebecque; Anas Gazzah; Capucine Baldini; Rastislav Bahleda; Benjamin Besse; Charlotte Rigaud; Véronique Minard‐Colin; Vincent Ribrag; Salim Laghouati; Élisabeth Chachaty; Fabrice Barlési; Aurélien Marabelle; O. Lambotte; Christophe Massard; Jean‐Marie Michot

doi:10.1093/cid/ciaf164

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

We investigated infectious complications and the associated risk factors in 181 patients undergoing T-cell engagers for malignancies. Infections were primarily observed in patients with hematological diseases or heavily pre-treated. Mortality due to infectious complications was 2.8%. Concomitant medications with corticosteroids or tocilizumab did not significantly impact the incidence of infections.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hueso et al. (2025) studied this question.

synapsesocial.com/papers/6a776ca6137c7dcc81bdd198 https://doi.org/10.1093/cid/ciaf164

View at Publisher

Ask AI

Bookmark

Share

Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From the REISAMIC Registry

Ask about this paper

Abstract

Discussion

Cite This Study

Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From the REISAMIC Registry

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading